P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Pharmacological Research

• Publication date

  1999-10-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1006/PHRS.1999.0535PMID 10527640
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of intestinal P-glycoprotein and effects on etoposide absorption

  2009cited by this paper
• Toxic digoxin-drug interactions: the major role of renal P-glycoprotein.

  1998cited by this paper
• Handbook of Drug Interactions

  1998cited by this paper
• Clinical relevance of transmembrane drug efflux as a mechanism of multidrug resistance.

  1998cited by this paper
• Co-administration of cyclosporin enables oral therapy with paclitaxel.

  1998cited by this paper
• Anaemia after enalapril in a child with nephrotic syndrome.

  1998cited by this paper
• The pharmacological role of P-glycoprotein in the intestinal epithelium.

  1998cited by this paper
• Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.

  1997cited by this paper
• Using the right drug. A treatment algorithm for atrial fibrillation.

  1997cited by this paper
• The effect of digoxin on mortality and morbidity in patients with heart failure.

  1997cited by this paper
• The functional role of P-glycoprotein in the blood-brain barrier.

  1997cited by this paper
• Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.

  1997cited by this paper
• Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.

  1997cited by this paper
• Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

  1997cited by this paper
• Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase--further experimental evidence for a multisite model.

  1997cited by this paper
• Effects of steroids and verapamil on P-glycoprotein ATPase activity: progesterone, desoxycorticosterone, corticosterone and verapamil are mutually non-exclusive modulators.

  1996cited by this paper
• P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

  1996cited by this paper
• Site-directed fluorescence labeling of P-glycoprotein on cysteine residues in the nucleotide binding domains.

  1996cited by this paper
• Co-operative, competitive and non-competitive interactions between modulators of P-glycoprotein.

  1996cited by this paper
• Substantial excretion of digoxin via the intestinal mucosa and prevention of long‐term digoxin accumulation in the brain by the mdrla P‐glycoprotein

  1996cited by this paper
• MDR expression in normal tissues. Pharmacologic implications for the clinical use of P-glycoprotein inhibitors.

  1995cited by this paper
• Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.

  1995cited by this paper
• Modulators of multidrug resistance. Preclinical studies.

  1995cited by this paper
• Clinical studies with modulators of multidrug resistance.

  1995cited by this paper
• P-glycoprotein expression and function in circulating blood cells from normal volunteers.

  1994cited by this paper
• The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1).

  1993cited by this paper
• P-glycoprotein-mediated renal tubular secretion of digoxin: the toxicological significance of the urine-blood barrier model.

  1993cited by this paper
• Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney.

  1993cited by this paper
• Biochemistry of multidrug resistance mediated by the multidrug transporter.

  1993cited by this paper
• Human Pharmacology: Molecular To Clinical

  1991cited by this paper
• Pharmacology of drugs that alter multidrug resistance in cancer.

  1990cited by this paper
• Verapamil-digoxin interaction in chronic hemodialysis patients.

  1990cited by this paper
• The biochemistry of P-glycoprotein-mediated multidrug resistance.

  1989cited by this paper
• Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

  1989cited by this paper
• Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.

  1987cited by this paper
• Mammalian multidrug resistance gene: complete cDNA sequence indicates strong homology to bacterial transport proteins.

  1986cited by this paper
• Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells.

  1986cited by this paper
• Digoxin intoxication induced by verapamil in an uremic patient.

  1985cited by this paper
• Digoxin intoxication induced by verapamil in an uremic patient.

  1985cited by this paper
• Digoxin interactions. The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides.

  1985cited by this paper
• The Influence of Verapamil on Serum Digoxin Concentration

  1982cited by this paper
• Acute and Chronic Pharmacodynamic Interaction of Verapamil and Digoxin in Atrial Fibrillation

  1982cited by this paper
• Digoxin‐verapamil interaction

  1981cited by this paper
• The Pharmacological Basis of Therapeutics

  1976cited by this paper
• Electrophysiology, Pacing, and Arrhythmia Atrial Fibrillation: A Review of Mechanism, Etiology, and Therapy

  year unknowncited by this paper

• Research Progress on the Mechanisms of Action, Pharmacological Activities and Clinical Application of P-glycoprotein Inhibitors.

  2026cites this paper
• Cluster-Validated Graph Neural Network for P-gp Substrate Prediction from Public Data.

  2026cites this paper
• Drug–Drug Interactions and Combination Therapy Strategies of Amiodarone With Digoxin, Rivaroxaban, and Phenytoin Assessed by Physiologically Based Pharmacokinetic Modeling

  2025cites this paper
• Glucosamine activates intestinal P-glycoprotein inhibiting drug absorption

  2025cites this paper
• Elucidating the Complex Structural and Molecular Mechanisms Driving P-Glycoprotein-Mediated Transport of Cardiac Glycosides

  2025cites this paper
• Predictive Modeling of Pharmacokinetic Drug–Drug and Herb–Drug Interactions in Oncology: Insights From PBPK Studies

  2025cites this paper
• Evaluation of the Effect of Lorlatinib on CYP2B6, CYP2C9, UGT, and P-Glycoprotein Substrates in Patients with Advanced Non-Small Cell Lung Cancer

  2023cites this paper
• Multimodal 4-arylchromene derivatives with microtubule-destabilizing, anti-angiogenic, and MYB-inhibitory activities

  2023cites this paper
• Drug–drug interactions and their implications on the pharmacokinetics of the drugs

  2022cites this paper
• Drug Interactions Affecting Antiarrhythmic Drug Use

  2022cites this paper
• Pediatric Drug‐Drug Interaction Evaluation: Drug, Patient Population, and Methodological Considerations

  2021cites this paper
• Interactions of human organic anion transporters 1-4 and human organic cation transporters 1-3 with the stimulant drug methamphetamine and amphetamine.

  2020cites this paper
• Pharmacokinetic drug-drug interactions: an insight into recent US FDA-approved drugs for prostate cancer.

  2020cites this paper
• A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

  2020cites this paper
• A COMPLETE GUIDE ON THE PHARMACOLOGIC AND PHARMACOTHERAPEUTIC ASPECTS OF CALCIUM CHANNEL BLOCKERS: AN EXTENSIVE REVIEW

  2019cites this paper
• Regulation of P-glycoprotein by Bajijiasu in vitro and in vivo by activating the Nrf2-mediated signalling pathway

  2019cites this paper
• Kobe University Repository : Kernel タイトル Tit le Reversal Effects of Ca 2 + Antagonists on Mult idrug Resistance via Down-regulat ion of MDR 1 mRNA 著者

  2019cites this paper
• Expression, Regulation und Funktion von Arzneistofftransportern in Caco-2-Zellen: ein biorelevantes in vitro-Modell für den intestinalen Arzneimitteltransport?

  2019cites this paper
• The Role of Transporters in Drug Accumulation and Mitochondrial Toxicity

  2018cites this paper
• Drug-Drug Interactions Mediated by P-Glycoprotein – An Overview

  2018cites this paper
• Interspecies comparison of putative ligand binding sites of human, rat and mouse P-glycoprotein

  2018cites this paper
• Mdr1a plays a crucial role in regulating the analgesic effect and toxicity of aconitine by altering its pharmacokinetic characteristics

  2017cites this paper
• Interaction of Food Additives with Intestinal Efflux Transporters.

  2017cites this paper
• Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine

  2016cites this paper
• Unravelling the complex drug–drug interactions of the cardiovascular drugs, verapamil and digoxin, with P-glycoprotein

  2016cites this paper
• Spica prunellae and its marker compound rosmarinic acid induced the expression of efflux transporters through activation of Nrf2-mediated signaling pathway in HepG2 cells.

  2016cites this paper
• Induction of P-glycoprotein expression and activity by Aconitum alkaloids: Implication for clinical drug–drug interactions

  2016cites this paper
• Toxicity of beauvericin on porcine oocyte maturation and preimplantation embryo development.

  2016cites this paper
• Comment on “Sweat but no gain”: Inhibiting proliferation of multidrug resistant cancer cells with “Ersatzdroges”

  2015cites this paper
• Frog intestinal perfusion to evaluate drug permeability: application to p-gp and cyp3a4 substrates

  2015cites this paper
• Quantitative Estimation of P-glycorptein-Mediated Drug Transport by Mechanistically Modeled Intrinsic Clearance

  2015cites this paper
• Management and Mitigation of Human Drug-drug Interaction Risks in the Drug Discovery and Development Phases

  2014cites this paper
• Is there more to learn about cytochrome P450 enzymes?

  2014cites this paper
• Long-term complete remission in a patient with intravascular large B-cell lymphoma with central nervous system involvement

  2014cites this paper
• P-Glycoprotein: A Focus on Characterizing Variability in Cardiovascular Pharmacotherapeutics

  2014cites this paper
• Mechanism of action of Xinmailong, a proprietary Chinese medicine for the treatment of chronic heart failure

  2014cites this paper
• Pharmacokinetic drug interactions involving Ginkgo biloba

  2013cites this paper
• Interaction of digitalis-like compounds with p-glycoprotein.

  2013cites this paper
• The P-glycoprotein transport system and cardiovascular drugs.

  2013cites this paper
• 123, and Rhodamine 6G Accumulation in Breast Cancer Cells that Overexpress P-Glycoprotein Microplate Screening of the Differential Effects of Test Agents on Hoechst 33342, Rhodamine

  2013cites this paper
• Berberine analogue IMB-Y53 improves glucose-lowering efficacy by averting cellular efflux especially P-glycoprotein efflux.

  2013cites this paper
• PREVALENCE, CLINICAL IMPORTANCE AND PREDICTORS OF POTENTIAL DRUG-DRUG INTERACTIONS IN DIFFERENT WARDS OF TERTIARY CARE HOSPITAL SETTING

  2012cites this paper
• Cardiac side population cells: moving toward the center stage in cardiac regeneration.

  2012cites this paper
• Digitalis toxicity: a fading but crucial complication to recognize.

  2012cites this paper
• Absence of Clinically Relevant Interactions between Rivaroxaban - an Oral, Direct Factor Xa Inhibitor - and Digoxin or Atorvastatin in Healthy Subjects

  2012cites this paper
• Polymorphismes du gène ABCB1 (MDR1) et impacts fonctionnels dans le transport de xénobiotiques - Particularités chez les sujets Noirs Subsahariens

  2012cites this paper
• Flavonoids and Drug Interactions

  2012cites this paper
• Psychotropic Drug–Drug Interactions Involving P-Glycoprotein

  2012cites this paper
• Different Effects of the Selective Serotonin Reuptake Inhibitors Fluvoxamine, Paroxetine, and Sertraline on the Pharmacokinetics of Fexofenadine in Healthy Volunteers

  2012cites this paper
• ABC multidrug transporters: target for modulation of drug pharmacokinetics and drug-drug interactions.

  2011cites this paper
• Choleretic Effect of ＂Curcuma longa＂ and Verapamil in Mice

  2011cites this paper
• BCRP (ABCG2) expression, function and regulation in model and intestinal epithelial cells

  2011cites this paper
• Prolonged Use of Aspirin Alters Human and Rat Intestinal Cells and Thereby Limits the Absorption of Clopidogrel

  2011cites this paper
• Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation.

  2011cites this paper
• Pregnane X receptor mediates the induction of P-glycoprotein by spironolactone in HepG2 cells.

  2011cites this paper
• Pharmacokinetics/Pharmacodynamics of Antiarrhythmic Drugs.

  2010cites this paper
• Modulation of the activity of ABC transporters (P-glycoprotein, MRP2, BCRP) by flavonoids and drug response.

  2010cites this paper
• P-Glycoprotein- and cytochrome P-450-mediated herbal drug interactions

  2010cites this paper
• Review of priorities in research on hormonal contraception and IUDs and HIV infection

  2010cites this paper
• Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician

  2010cites this paper
• Automated Drug Screening for ADMET Properties

  2010cites this paper
• Web-Based Database as a Tool to Examine Drug–Drug Interactions Involving Transporters

  2010cites this paper
• Interactions between verapamil and digoxin in Langendorff-perfused rat hearts: the role of inhibition of P-glycoprotein in the heart.

  2010cites this paper
• Pharmacologic Interactions in the CICU

  2010cites this paper
• Lactone-carboxylate interconversion as a determinant of the clearance and oral bioavailabilty of the lipophilic camptothecin analog AR-67

  2010cites this paper
• Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice

  2010cites this paper
• Evidence for the Interplay Between ABCG 2 and Hypertension : Increased Risk of Stroke and Coronary Artery Disease

  2009cites this paper
• Prevalence of adverse drug combinations in a large post-mortem toxicology database

  2009cites this paper
• The Effect of Loperamide and Fentanyl on the Distribution Kinetics of Verapamil in the Lung and Brain in Sprague Dawley Rats

  2009cites this paper
• Biological actions and metabolism of currently used pharmacological agents for the treatment of congestive heart failure.

  2009cites this paper
• Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression.

  2009cites this paper
• Unveiling the Role of Multidrug Resistance Proteins in Hypertension

  2009cites this paper
• Concentration-Dependent Effect of Naringin on Intestinal Absorption of β1-Adrenoceptor Antagonist Talinolol Mediated by P-Glycoprotein and Organic Anion Transporting Polypeptide (Oatp)

  2009cites this paper
• Inhibition of P-glycoprotein in Caco-2 cells: Effects of herbal remedies frequently used by cancer patients

  2008cites this paper
• Reversal Effects of Ca 2 + Antagonists on Multidrug Resistance via Down-regulation of MDR 1 mRNA

  2008cites this paper
• P-Glycoprotein Efflux Transporter Activity Often Displays Biphasic Dose-Response Relationships

  2008cites this paper
• Dietary salt does not influence the disposition of verapamil enantiomers in relation to efflux transporter ABCB1 genetic polymorphism in healthy Korean subjects

  2008cites this paper
• Implications of ABC transporters on the disposition of typical veterinary medicinal products.

  2008cites this paper
• Lack of a pharmacokinetic interaction between a new smoking cessation therapy, varenicline, and digoxin in adult smokers

  2008cites this paper
• Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.

  2008cites this paper
• Reversal effects of Ca2+ antagonists on multidrug resistance via down-regulation of MDR1 mRNA.

  2008cites this paper
• Adverse drug reactions in patients with cardiovascular disease.

  2008cites this paper
• Herbal Pharmacokinetics : A Practitioner Update With Reference to St . John ’ s Wort ( Hypericum perforatum )

  2008cites this paper
• Permeability--in vitro assays for assessing drug transporter activity.

  2008cites this paper
• Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure.

  2008cites this paper
• Role of ATP-binding cassette transporters in drug distribution to the heart and protection from toxic compounds

  2007cites this paper
• Pharmacokinetic and pharmacogenetic profiling in solid cancer patients

  2007cites this paper
• Equilibrative and Concentrative Transport Mechanisms

  2007cites this paper
• Expression of Adenosine Triphosphate-Binding Cassette (ABC) Drug Transporters in Peripheral Blood Cells

  2007cites this paper
• CHAPTER 15 – Drug Interactions

  2007cites this paper
• P-glycoprotein and membrane permeability as determinants of xenobiotic bioavailability and bioaccumulation

  2007cites this paper
• Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).

  2007cites this paper
• [Pharmaceutical support in the cardiovascular and cardiovascular surgery ward].

  2007cites this paper
• Transporter-mediated drug interactions: clinical implications and in vitro assessment

  2007cites this paper
• Species differences of inhibitory effects on P-glycoprotein-mediated drug transport.

  2007cites this paper
• Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein.

  2006cites this paper
• Multidrug resistance 1 gene in inflammatory bowel disease: a meta-analysis.

  2006cites this paper
• Interacciones medicamentosas. Nuevos aspectos

  2006cites this paper
• IN VITRO P-GLYCOPROTEIN INHIBITION ASSAYS FOR ASSESSMENT OF CLINICAL DRUG INTERACTION POTENTIAL OF NEW DRUG CANDIDATES: A RECOMMENDATION FOR PROBE SUBSTRATES

  2006cites this paper
• P-glycoprotein: pharmacological relevance

  2006cites this paper